Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +48.81%
#3 Black Phoenix Black Phoenix +34.68%
#4 Velvet Velvet +29.04%
#5 Cross Cross +22.45%
#6 Akedo Akedo +17.41%
#7 DoubleZero DoubleZero +14.34%
#8 Cap Cap +11.68%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.22%
#10 HOME HOME +10.23%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Clasificación en acciones #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Precio por acción
$17.15
Última sincronización: 2026-08-03
Capitalización bursátil
$6.51M
Cambio (1 día)
9.80%
Cambio (1 año)
289.77%
País
US
Comercio Galera Therapeutics, Inc. (GRTX)

Categoría

Healthcare
Ingresos de Galera Therapeutics, Inc. (GRTX)
Ingresos en Mar 2026 TTM: 0.00
Según los últimos informes financieros de Galera Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0.00. En 2023, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2022, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Galera Therapeutics, Inc. desde 2017 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE